Brokerages Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Target Price at $11.00

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $11.00.

EVAX has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Evaxion A/S in a research note on Friday, April 24th. Weiss Ratings raised Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. Finally, Wall Street Zen cut Evaxion A/S from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Rathbones Group PLC acquired a new stake in shares of Evaxion A/S during the first quarter valued at about $170,000. Renaissance Technologies LLC acquired a new position in shares of Evaxion A/S in the 1st quarter worth approximately $146,000. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Evaxion A/S in the 1st quarter worth approximately $112,000. SmartHarvest Portfolios LLC purchased a new position in shares of Evaxion A/S during the 4th quarter worth approximately $72,000. Finally, Wesbanco Bank Inc. purchased a new position in shares of Evaxion A/S during the 4th quarter worth approximately $48,000. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion A/S Stock Up 0.7%

Shares of NASDAQ EVAX opened at $3.05 on Thursday. The company has a market capitalization of $25.44 million, a P/E ratio of -2.07 and a beta of 0.26. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.85 and a quick ratio of 5.85. The company has a 50 day simple moving average of $3.62 and a 200-day simple moving average of $3.84. Evaxion A/S has a 1 year low of $2.45 and a 1 year high of $12.15.

Evaxion A/S (NASDAQ:EVAX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.43). On average, equities research analysts predict that Evaxion A/S will post -0.5 earnings per share for the current year.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.